A comparative trial of metabolic parameters and cardiovascular risk in chronic hepatitis B patients who were treated with Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
Phase 4
Completed
- Conditions
- Chronic hepatitis B infectionHBV
- Registration Number
- TCTR20220209003
- Lead Sponsor
- Faculty of medicine, Siriraj Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
1.Chronic HBV infection patient, age 40-75 yr.
2.Currently on TDF at least 1 yr and undetectable HBV viral load
3.Estimated GFR > 50 ml/min/1.73m
4.LDL cholesterol < 130 ml/dL more than 6 months or < 100 ml/dL in DM
Exclusion Criteria
1.Co-infection with HCV or HIV
2.Patients who currently had other cancer or HCC
3.Patients who had cirrhosis or clinical liver decompensatiom
4.Previous organ transplantation
5.Previous diagnosed with stroke or coronary artery disease
6.Currently on immunosuppresive drugs
7.Patients whom plan to pregnant or current pregnant
8.Initial carotid doppler ultrasonography show carotid stenosis > 70%
9.Patients who had history of alcohol drinking > 2 standard drinks in male or > 1 standard drink in female
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method DL cholesterol at 6,12 month after starting point of intervention mg/d
- Secondary Outcome Measures
Name Time Method